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Background: Excess visceral adipose tissue (VAT) is closely associated with the presence of coronary artery plaques
that are vulnerable to rupture. Patients with diabetes mellitus (DM) have more VAT than patients without DM, but
the extent to which VAT contributes to the characteristics of coronary plaques before and after the development of
DM is not fully understood.
Methods: We retrospectively evaluated 456 patients (60% male, age 64 ± 16 years) who were suspected to have
cardiovascular disease and underwent 64-slice computed tomography angiography (CTA). Seventy-one (16%)
patients had vulnerable plaques (CT density < 50 Hounsfield Units, positive remodeling index > 1.05, and adjacent
spotty areas of calcification).
Results: Patients were divided into tertiles according to the VAT area. There were stepwise increases in noncalcified
and vulnerable plaques with increasing tertiles of VAT area in patients without DM, but not in patients with DM.
Multivariate analysis showed that a larger VAT area was significantly associated with a higher risk of vulnerable
plaque in patients without DM (odds ratio 3.17, 95% confidence interval 1.08–9.31, p = 0.04), but not in patients
with DM.
Conclusions: The VAT area is associated with the characteristics of coronary plaques on CTA in patients without
DM, but not in patients with DM. VAT may be a significant cardiometabolic risk factor that is associated with plaque
vulnerability before the development of DM. CTA findings may help to improve risk stratification in such patients.
Keywords: Visceral adipose tissue, Coronary artery disease, Diabetes mellitusBackground
Obesity is one of the most common causes of cardiovas-
cular morbidity and mortality [1]. The body mass index
(BMI) has been used to evaluate the impact of obesity
on cardiovascular disease, but recent studies have shown
that the amount of visceral adipose tissue (VAT) evalu-
ated by the waist-to-hip ratio or computed tomography
(CT) findings is more closely associated with cardiovas-
cular events than BMI [2,3]. VAT is an endocrine organ
that produces large amounts of adipokines. A large* Correspondence: miyoshit@cc.okayama-u.ac.jp
2Department of Cardiovascular Therapeutics, Dentistry and Pharmaceutical
Sciences, Okayama University Graduate School of Medicine, 2-5-1
Shikata-cho, Okayama 700-8558, Japan
Full list of author information is available at the end of the article
© 2014 Osawa et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.amount of VAT leads to adipose tissue dysfunction
followed by impaired insulin sensitivity, secretion of pro-
inflammatory adipokines, and ultimately type 2 diabetes
mellitus (DM), left ventricular dysfunction, and coronary
artery disease (CAD) [4-8].
Recent advances in cardiac CT angiography (CTA)
technology have enabled noninvasive detection of non-
calcified plaques (NCPs) and evaluation of the charac-
teristics of vulnerable NCPs in terms of CT density,
remodeling, and adjacent spotty areas of calcification
[9,10]. Vulnerable plaques have an increased risk of rup-
ture resulting in adverse coronary events [9,11]. The
amount of VAT is closely associated with the character-
istics of vulnerable coronary artery plaques [12-14].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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DM [15,16], but the extent to which VAT contributes to
the NCP burden and to the vulnerability of NCPs before
and after the development of DM is not fully under-
stood. The objective of this study was to evaluate the re-
lationships between the characteristics of coronary
plaques identified by CTA and the amount of VAT in
patients with and without DM.
Methods
Study population
The study population included 502 consecutive patients
who underwent 64-slice CT because of suspected stable
coronary artery disease (effort angina pectoris or vaso-
spastic angina pectoris) at Okayama University Hospital
between August 2011 and December 2012. Patients with
a history of coronary artery stenting (n = 28) or coronary
artery bypass graft surgery (n = 6) were excluded. Pa-
tients in whom some coronary artery segments could
not be evaluated because of motion artifacts or inad-
equate contrast filling (n = 16), or who had missing ab-
dominal scans or missing information regarding one or
more traditional coronary risk factors (n = 2), were also
excluded. Some patients had more than one reason for
exclusion, and 456 patients were included in this study.
The study protocol was approved by the institutional
ethics committee on human research of Okayama Uni-
versity. Written informed consent was obtained from all
patients before inclusion in the study. The investigation
conformed to the principles outlined in the Declaration
of Helsinki.
Multi-detector CT imaging protocol
Subjects underwent radiographic assessment of the chest
and abdomen in the supine position during one proced-
ure. CT imaging was performed using a Somatom Defin-
ition Flash scanner (Siemens Medical Solutions, Erlangen,
Germany) [17]. The parameters were as follows: detector
collimation 64 × 0.6 mm (equivalent to slice acquisition of
128 × 0.6 mm using the flying focal spot technique), table
pitch adjusted to heart rate (0.17–0.38), rotation time
275 ms, tube current time product 360 mAs, and tube
voltage 120 kVp. A test bolus of 10 mL of contrast
medium followed by 20 mL of saline was injected at the
level of the ascending aorta, and low-dose CT images were
obtained every 1 s. The delay before the formal scan was
calculated as the time to peak enhancement in the ascend-
ing aorta plus 3 s, to ensure enhancement of the distal seg-
ments of the coronary arteries. For the final scan, contrast
agent (Omnipaque 350; Daiichi Sankyo, Tokyo, Japan) was
injected over 10 s, followed by a second bolus of 80% of
the amount of contrast medium diluted 50% and then a
bolus of saline. All injections were administered at the
same rate, calculated as the body weight × 0.07 mL/s. Allpatients arrived at the hospital 1 h before the scheduled
CT time, and those with a persistent heart rate of ≥60
beats/min received oral metoprolol (20–40 mg). If the
heart rate did not decrease to <60 beats/min before
the scheduled CT time, patients received additional pre-
medication such as oral metoprolol (20 mg), intravenous
propranolol (2 mg), intravenous verapamil (5 mg), and/or
intravenous landiolol hydrochloride (0.125 mg/kg) until
the heart rate was <60 beats/min.
CTA analysis
Coronary artery stenosis and plaques were evaluated on
axial and curved multiplanar reformatted images using
commercially available cardiac reconstruction software
(Virtual Place, Raijin; AZE Inc., Tokyo, Japan). One ex-
perienced and trained senior cardiologist and two senior
CT technicians performed the analyses, and evaluations
were performed on a per-segment basis. Sixteen seg-
ments were identified based on the established American
Heart Association segment model, and the presence and
characteristics of coronary artery plaques on CTA were
evaluated. The minimum CT density was measured in at
least five regions of interest (each 1 mm2). Coronary pla-
ques were defined as structures of > 1 mm2 within the
coronary arteries that differed in density from the
contrast-enhanced vessel lumen. Plaques were catego-
rized as calcified plaques (> 130 Hounsfield Units [HU]),
NCPs (< 130 HU), or low-density plaques (< 50 HU).
Coronary artery remodeling was assessed by calculation
of the difference in vessel diameter at the plaque site
compared with a reference site in a normal-appearing
segment proximal to the lesion, with positive remodeling
defined as an index of > 1.05, as previously described
[18]. An area of spotty calcification was defined as fol-
lows: length (in the longitudinal direction of the vessel)
of the calcification < 3/2 of the vessel diameter, and
width (perpendicular to the longitudinal direction of the
vessel) of the calcification < 2/3 of the vessel diameter.
Vulnerable plaque was defined as plaque with all of the
following characteristics: positive remodeling, low dens-
ity, and an adjacent area of spotty calcification. Signifi-
cant coronary artery stenosis was defined as luminal
obstruction of > 50% of the diameter of the vessel. The
inter-observer coefficient of variation of 20 randomly
selected samples was < 5%.
Abdominal tissue measurements
Abdominal CT at the level of the umbilicus was per-
formed at the same time as cardiac CT. The VAT area,
subcutaneous adipose tissue (SAT) area, and waist cir-
cumference (WC) were assessed using Virtual Place soft-
ware. WC was calculated automatically at the level of
the umbilicus. Fat volume was measured using the semi-
automatic segmentation technique [19]. The attenuation
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standard deviations of the mean in each individual. The
muscular abdominal wall was manually traced to separ-
ate VAT from SAT.
Assessment of other risk factors
DM was defined as self-reported history of DM,
hemoglobin A1c (HbA1c) level of > 6.5% [20], or current
use of hypoglycemic agents. Dyslipidemia was defined as
current use of lipid-lowering agents, or a low-density lipo-
protein cholesterol level of ≥ 140 mg/dl, triglyceride level
of ≥ 150 mg/dl, or high-density lipoprotein cholesterol
(HDL-cholesterol) level of < 40 mg/dl in a fasting blood
sample. Hypertension was defined as a sitting blood pres-
sure of ≥ 140/90 mmHg or current use of antihypertensive
agents [21]. Smoking status was categorized as currently
smoking or not smoking. BMI was defined as the body
weight (kg) divided by the square of the height (m2). Ven-
ous blood samples were collected at the outpatient clinic
after an overnight fast of 8–12 hours. Serum levels of
lipids (total cholesterol, HDL-cholesterol, and triglycer-
ides), HbA1c, and high-sensitivity C-reactive protein
(hsCRP) were measured by routine methods using an
AutoAnalyzer at the central laboratory of Okayama Uni-
versity Hospital.
Statistical analysis
Continuous variables are presented as the mean ± standard
deviation or median (interquartile range). Data that were
not normally distributed according to the Kolmogorov–
Smirnov test were logarithmically transformed before
analysis. Categorical variables are presented as frequency
(percentage). Continuous and categorical variables were
compared between groups using the unpaired Student’s t-
test or the chi-square test, as appropriate. Correlations be-
tween the VAT area and the numbers of areas with various
plaque characteristics were determined using the Spearman
rank correlation test. The VAT area was categorized into
tertiles (T1, T2, and T3). For all patients, T1 ≤ 65.6 cm2
(n = 152), 65.6 cm2 < T2 ≤ 114.5 cm2 (n = 152), and T3 >
114.5 cm2 (n = 152). For patients with DM, T1 ≤ 87 cm2
(n = 40), 87 < T2 ≤ 130.0 cm2 (n = 41), and T3 > 130.0 cm2
(n = 41). For patients without DM, T1 ≤ 60 cm2 (n = 111),
60 < T2 ≤ 106 cm2 (n = 112), and T3 > 106 cm2 (n = 111).
Multivariate logistic regression analyses were performed to
assess whether the associations between vulnerable plaque
and VAT area were independent of age, sex, hypertension,
dyslipidemia, and current smoking. A p value < 0.05 was
considered statistically significant. All statistical analyses
were performed using SPSS 17.0 for Windows (SPSS Inc.,
Chicago, IL). Receiver operating characteristic (ROC) curve
analysis was used to determine the specificity and sensitivity
of the VAT area for differentiating between patients with
and without vulnerable plaque.Results
Table 1 shows the clinical characteristics of subjects with
and without DM. A total of 456 patients (57% male)
with a mean age of 64 ± 14 years (range 16–92 years)
were included in our analyses. Vulnerable plaques were
detected in 17 (16%) of the 456 patients. Patients with
DM were more likely to be male and had a higher BMI,
larger WC, larger VAT area, higher prevalence of hyper-
tension and dyslipidemia, and higher triglyceride level
than patients without DM.
Table 2 shows the baseline characteristics according to
the VAT area tertile in patients with and without DM. In
patients without DM, the T3 group had a higher propor-
tion of men, more advanced age, higher prevalence of
hypertension and use of antihypertensive agents, higher
prevalence of dyslipidemia and use of lipid-lowering
agents, lower level of HDL-cholesterol, and higher levels
of triglycerides, HbA1c, and hsCRP than the T1 group.
In patients with DM, the T3 group had a higher propor-
tion of men, higher prevalence of hypertension and use
of antihypertensive agents, and higher triglyceride level
than the T1 group.
Figure 1 shows the prevalence of plaque characteristics
according to the VAT area tertile in patients with and with-
out DM. In patients with DM, there were no significant
differences in the prevalence of any of the plaque charac-
teristics among the tertiles. In patients without DM, there
was a stepwise increase in the prevalence of each plaque
characteristics from the T1 group to the T3 group. The T1
group had a lower prevalence than the T2 and T3 groups
of positive remodeling (25 vs. 47 and 50%, p < 0.01), low-
density plaques (9 vs. 22 and 24%, p < 0.01), adjacent areas
of spotty calcification (5 vs. 14 and 22%, p = 0.01), and all
three of these characteristics (5 vs. 14 and 21%, p = 0.02).
Figure 2 shows the prevalence of plaque characteristics ac-
cording to the BMI tertile in patients with and without
DM. In patients without DM, there were no significant dif-
ferences in the prevalence of calcified plaque, NCP, or posi-
tive remodeling among the tertiles. In patients with DM,
the T2 group tended to have a higher prevalence of calci-
fied plaque and positive remodeling than the T1 and the
T3 groups. There was no significant difference in the
prevalence of vulnerable plaques among the BMI tertiles.
Figure 3 shows the prevalence of plaque characteristics ac-
cording to the WC tertile in patients with and without
DM. In patients without DM, the T1 group had a signifi-
cantly lower prevalence of vulnerable plaque than the T2
group. Patients with DM had a similar trend in terms of
the prevalence of vulnerable plaque among tertiles, but the
differences were not significant. Figure 4 shows the preva-
lence of plaque characteristics according to the SAT tertile
in patients with and without DM. In patients with and
without DM, there was no significant difference in the
prevalence of vulnerable plaque among tertiles.
Table 1 Baseline characteristics of subjects with and without DM
All (n = 456) Without DM (n = 334) With DM (n = 122) p
Age (years) 64 ± 14 64 ± 15 66 ± 12 0.15
Men, n (%) 261 (57) 182 (54) 79 (65) 0.04
Body mass index (kg/m2) 23 ± 4 23 ± 3 25 ± 4 <0.01
Waist circumference (cm) 84 ± 11 82 ± 10 88 ± 11 <0.01
Subcutaneous adipose tissue (cm2) 136 ± 79 132 ± 76 147 ± 84 0.08
Visceral adipose tissue (cm2) 95 ± 55 88 ± 52 116 ± 58 <0.01
Hypertension, n (%) 263 (58) 176 (53) 87 (71) <0.01
Dyslipidemia, n (%) 208 (46) 130 (39) 78 (66) <0.01
Current smoking, n (%) 98 (21) 72 (22) 26 (21) 0.96
Total cholesterol (mg/dl) 187 ± 37 188 ± 38 187 ± 36 0.95
Triglycerides (mg/dl) 143 (88) 138 (107) 154 (121) 0.02
HDL-cholesterol (mg/dl) 57 ± 16 58 ± 16 56 ± 17 0.16
LDL-cholesterol (mg/dl) 111 ± 32 111 ± 33 110 ± 30 0.93
Hemoglobin A1c (%) 6.2 ± 1.2 5.7 ± 0.4 7.4 ± 1.6 <0.01
High sensitivity CRP (mg/dl) 0.16 (0.08) 0.15 (0.08) 0.17 (0.09) 0.30
Medications
Antihypertensive agents, n (%) 239 (52) 160 (48) 79 (65) <0.01
Lipid lowering agents n (%) 138 (30) 84 (25) 54 (44) <0.01
Hypoglycemic agents, n (%) 82 (18) 0 (0) 82 (67) <0.01
DM, diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein.
Table 2 Baseline characteristics according to the VAT area tertile in patients with and without DM
Without DM (n = 334) With DM (n = 122)
Characteristic VAT T1 (n = 111) VAT T2 (n = 112) VAT T3 (n = 111) VAT T1 (n = 40) VAT T2 (n = 41) VAT T3 (n = 41)
Age (years) 58 ± 19 66 ± 13* 67 ± 11* 65 ± 14 67 ± 11 65 ± 12
Men, n (%) 45 (41) 60 (54) 77 (69)*† 23 (58) 21 (51) 35 (85)*†
Body mass index (kg/m2) 20 ± 2 23 ± 2* 25 ± 3*† 22 ± 3 25 ± 4* 27 ± 4*†
Waist circumference (cm) 74 ± 7 82 ± 6* 91 ± 8*† 80 ± 8 88 ± 9* 96 ± 10*†
Subcutaneous adipose tissue (cm2) 91 ± 63 131 ± 58* 175 ± 82*† 112 ± 72 151 ± 79* 177 ± 90*
Visceral adipose tissue (cm2) 35 ± 15 82 ± 13* 147 ± 39*† 55 ± 22 111 ± 13* 180 ± 41*†
Hypertension, n (%) 47 (42) 59 (53) 70 (63)* 23 (58) 31 (76) 33 (80)*
Dyslipidemia, n (%) 26 (23) 48 (43)* 56 (50)* 25 (63) 25 (61) 28 (68)
Current smoking, n (%) 18 (16) 25 (22) 29 (26) 11 (28) 6 (15) 9 (22)
Total cholesterol (mg/dl) 184 ± 39 192 ± 37 189 ± 38 185 ± 40 187 ± 34 189 ± 34
Triglycerides (mg/dl) 92 (51) 149 (88)* 169 (103)* 106 (46) 154 (78) 200 (165)*†
HDL-cholesterol (mg/dl) 63 ± 17 57 ± 15* 53 ± 15* 60 ± 19 54 ± 14 53 ± 19*
LDL-cholesterol (mg/dl) 108 ± 33 115 ± 32 109 ± 34 107 ± 28 113 ± 29 109 ± 34
Hemoglobin A1c (%) 5.5 ± 0.3 5.7 ± 0.4* 5.8 ± 0.5*† 7.4 ± 1.6 7.5 ± 1.6 7.4 ± 1.7
High sensitivity CRP (mg/dl) 0.16 (0.14) 0.15 (0.12) 0.16 (0.13)* 0.14 (0.11) 0.16 (0.20) 0.20 (0.22)
Medications
Antihypertensive agents, n (%) 44 (40) 50 (45) 66 (59)*† 21 (53) 27 (66) 31 (76)*
Lipid-lowering agents, n (%) 15 (14) 32 (29)* 37 (33)* 20 (50) 11 (27)* 23 (56)†
Hypoglycemic agents, n (%) 0 (0) 0 (0) 0 (0) 22 (55) 29 (71) 30 (73)
DM, diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c.
The VAT area data were divided into tertiles (T) as described in the Methods. *p < 0.05 vs. T1 group, †p < 0.05 vs. T2 group.
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Figure 1 Prevalences of plaque characteristics according to VAT area tertile in patients with and without DM. CP, calcified plaque; NCP,
noncalcified plaque; PR, positive remodeling; LDP, low-density plaque; SC, spotty calcification. *p < 0.05 vs. T1 group; †p < 0.05 vs. T2 group.
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characteristics according to the VAT area tertile in pa-
tients with and without DM. The numbers of calcified
plaques, NCPs, mixed plaques, vulnerable plaques, and
significant stenoses were significantly higher in the T3
group than in the T1 group in patients without DM.
There was a stepwise increase in the coronary artery cal-
cium score from the T1 group to the T3 group in pa-
tients without DM, but not in patients with DM. This
association remained significant after adjustment for age
(Table 4).Figure 2 Prevalences of plaque characteristics according to BMI tertil
noncalcified plaque; PR, positive remodeling; LDP, low-density plaque; SC, sTable 5 shows associations between vulnerable plaque
and clinical variables and VAT area tertiles in patients
with and without DM. In patients without DM, univari-
ate analysis showed that VAT area T2 and T3, older age,
male sex, current smoking, and lower HDL-cholesterol
level were significantly associated with vulnerable
plaque. Multivariate analysis showed that VAT area T3
was significantly associated with vulnerable plaque even
after adjustment for confounding factors in patients
without DM (odds ratio 3.17, 95% confidence interval
[CI] 1.08–9.31, p = 0.04; Table 6). In patients with DM,e in patients with and without DM. CP, calcified plaque; NCP,
potty calcification. *p < 0.05 vs. T1 group; †p < 0.05 vs. T2 group.
Figure 3 Prevalences of plaque characteristics according to WC tertile in patients with and without DM. CP, calcified plaque; NCP,
noncalcified plaque; PR, positive remodeling; LDP, low-density plaque; SC, spotty calcification. *p < 0.05 vs. T1 group.
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(Table 6).
Table 6 shows the associations between adiposity vari-
ables and vulnerable plaque. In patients without DM,
VAT area T3, BMI T2, and WC T2 were independently
associated with vulnerable plaque after adjustment for
age, sex, smoking, hypertension, and dyslipidemia. There
were no associations between adiposity and vulnerable
plaque in patients with DM.
ROC curve analysis of the VAT area in patients with-
out DM showed an optimal cutoff value of 91.3 cm2 forFigure 4 Prevalences of plaque characteristics according to SAT tertil
noncalcified plaque; PR, positive remodeling; LDP, low-density plaque; SC, sidentification of patients with vulnerable plaque, with
sensitivity of 70%, specificity of 62%, and area under the
curve of 0.69 (95% CI 0.61–0.77, p < 0.01). In patients
with DM, the area under the curve was 0.48 (95% CI
0.37–0.58, p = 0.71) (data not shown).
Discussion
The results of this study show that a large VAT area is
associated with various characteristics of vulnerable cor-
onary artery plaques on CTA in patients without DM,
but not in patients with DM. The prevalence ofe in patients with and without DM. CP, calcified plaque; NCP,
potty calcification. †p < 0.05 vs. T2 group.
Table 3 Numbers of plaques with various characteristics according to VAT area tertiles in patients with and without DM
Without DM (n = 334) With DM (n = 122)
Characteristics VAT T1 (n = 111) VAT T2 (n = 112) VAT T3 (n = 111) VAT T1 (n = 40) VAT T2 (n = 41) VAT T3 (n = 41)
Calcified plaque 1.7 ± 2.3 2.1 ± 2.7 3.0 ± 3.1*† 3.4 ± 3.4 3.3 ± 3.3 4.8 ± 3.7
Noncalcified plaque 0.7 ± 1.3 1.3 ± 1.6* 1.6 ± 2.0* 2.1 ± 2.2 2.0 ± 2.2 2.4 ± 2.1
Mixed plaque 0.5 ± 0.9 0.9 ± 1.2* 1.2 ± 1.7* 1.3 ± 1.6 1.3 ± 1.9 1.7 ± 1.8
Vulnerable plaque 0.2 ± 0.6 0.3 ± 0.5 0.3 ± 0.7* 0.6 ± 1.1 0.6 ± 1.0 0.5 ± 0.8
Significant stenosis 0.3 ± 0.7 0.3 ± 0.8 0.6 ± 1.3*† 0.6 ± 1.1 0.6 ± 1.2 0.8 ± 1.2
Coronary artery calcium score 177 (156) 207 (145) 307 (270) 461 (746) 380 (241) 495 (958)
*p < 0.05 vs. T1 group; †p < 0.05 vs. T2 group.
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patients with DM (about 20%) and in the highest VAT
area tertile in patients without DM. These findings sup-
port the hypothesis that a large VAT area is a cardiomet-
abolic risk factor that is significantly associated with
vulnerable plaque before the development of DM, and
that measurement of the VAT area is useful for assessing
cardiovascular risk in patients without DM.
The results of this study show a positive association
between a large VAT area and the NCP burden on CTA
in patients without DM, but not in patients with DM.
Several previous studies reported that the VAT area was
an independent marker of CAD [13,22]. Excess VAT
triggers insulin resistance, which may be accompanied
by release of inflammatory mediators and cytokines from
dysfunctional adipose tissue and may be strongly associ-
ated with the formation and progression of coronary
artery plaques. The different associations of the VAT
area with characteristics of coronary plaques in different
groups in this study may be explained by variations in
HDL-cholesterol and HbA1c levels, which are known to
be associated with cardiovascular risk [23,24]. In patients
without DM, the HDL- cholesterol and HbA1c levels
changed unfavorably with increasing VAT area tertiles,
whereas in patients with DM, these factors were not sig-
nificantly different among the VAT area tertiles. The
hsCRP level was significantly higher in the VAT area T3
group than in the T1 and T2 groups in patients without
DM, but was not significantly different among tertilesTable 4 Age-adjusted associations between numbers of





Without DM (n = 334) With DM (n = 122)
ρ p ρ p
Calcified plaque 0.12 0.03 0.08 0.37
Noncalcified plaque 0.16 <0.01 -0.01 0.89
Mixed plaque 0.15 <0.01 0.05 0.61
Vulnerable plaque 0.15 <0.01 -0.03 0.78in patients with DM. Another explanation is that hyper-
glycemia may be the main factor determining cardiovas-
cular risk in patients with DM, and may override the
effects of excess VAT-dependent inflammatory mediators
and cytokines. Oxidative stress caused by hyperglycemia
[25] and advanced glycation end products [26] may have
greater effects on plaque characteristics in patients with
DM than in patients without DM, and may attenuate the
impact of the VAT area. However, our findings are not
consistent with those of a cross-sectional study which
reported that the amount of VAT was strongly associ-
ated with cardiometabolic risk factors regardless of type
2 diabetes status [27]. This difference may be partly
owed to differences in ethnicity of the study populations.
The previous study was conducted in a population that
included only 8.2% East Asian individuals, and did not
include patients with suspected CAD, both of which
were characteristics of our study subjects. Another study
reported that the amount of VAT was not an independent
coronary risk factor after adjustment for multiple covari-
ates, although VAT was one of the variables influencing
the development of atherosclerosis [28]. This is consistent
with our hypothesis that visceral obesity is an important
coronary risk factor, but precedes the development of DM.
In patients without DM in this study, hypertension, dyslip-
idemia, and high triglyceride level tended to be associated
with vulnerable plaque, but these associations were not
statistically significant. A large amount of VAT increased
the risks of cardiovascular risk factors such as hyperten-
sion and dyslipidemia, but these factors may not have suf-
ficient individual impact to lead to the development of
vulnerable coronary plaques. In other words, the amount
of VAT is considered to be a representative marker of car-
diometabolic risk, and may therefore be associated with
plaque characteristics.
In this study, the highest tertile of the VAT area in-
cluded a higher proportion of men than the other ter-
tiles in patients with and without DM. Although there
were no significant differences between males and fe-
males in the majority of cardiovascular risk factors, HDL
and triglyceride levels have been reported to have a
Table 5 Factors associated with vulnerable plaque in patients with and without DM
Without DM (n = 334) With DM (n = 122)
Factor Odds ratio (95% CI) p Odds ratio (95% CI) p
Age (per year) 1.04 (1.01–1.07) <0.01 1.02 (0.99–1.07) 0.22
Male sex 5.11 (2.20–11.85) <0.01 1.86 (0.72–4.82) 0.20
Hypertension 1.61 (0.83–3.11) 0.16 1.64 (0.60–4.46) 0.34
Dyslipidemia 1.42 (0.74–2.71) 0.28 1.25 (0.51–3.07) 0.62
Current smoking 3.16 (1.61–6.20) <0.01 0.76 (0.26–2.23) 0.61
Total cholesterola 0.80 (0.02–30.28) 0.90 0.10 (0.001–21.32) 0.40
Triglyceridesa 2.39 (0.64–8.87) 0.19 2.48 (0.39–15.87) 0.34
HDL-cholesterola 0.025 (0.001–0.49) 0.02 0.43 (0.016–11.25) 0.61
LDL-cholesterola 6.50 (0.44–96.74) 0.17 0.13 (0.003–4.84) 0.27
Hemoglobin A1c 1.86 (0.88–3.91) 0.10 1.02 (0.78–1.33) 0.90
High sensitivity CRPa 1.04 (0.50-2.18) 0.91 1.36 (0.52-3.55) 0.53
VAT T1 1.00 1.00 1.00 1.00
VAT T2 3.28 (1.15–9.36) 0.03 1.26 (0.46–3.48) 0.65
VAT T3 5.54 (2.02–15.18) <0.01 0.84 (0.29–2.44) 0.74
Antihypertensive agents 1.29 (0.68–2.46) 0.43 0.97 (0.40–2.35) 0.95
Lipid-lowering agents 1.34 (0.66–2.71) 0.41 1.63 (0.70–3.80) 0.26
Hypoglycemic agents Not available 1.09 (0.44–2.68) 0.85
The VAT area data were divided into tertiles (T) as described in the Methods.
aValues were log-transformed before analysis.
DM, diabetes mellitus; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VAT, visceral adipose tissue.
Table 6 Associations between adiposity measurements and vulnerable plaque
Without DM (n = 334) With DM (n = 122)
Univariate Multivariate Univariate
Odds ratio (95% CI) p Odds ratio (95% CI) p Odds ratio (95% CI) p
Visceral adipose tissue:
T1 1 1
T2 3.28 (1.15–9.36) 0.03 2.32 (0.77–6.97) 0.13 1.26 (0.46–3.48) 0.65
T3 5.54 (2.02–15.18) <0.01 3.17 (1.08–9.31) 0.04 0.84 (0.29–2.44) 0.74
Subcutaneous adipose tissue:
T1 1 1
T2 1.74 (0.82–3.68) 0.14 1.81 (0.81–4.05) 0.15 1.86 (0.67–5.13) 0.23
T3 0.67 (0.27–1.63) 0.37 1.14 (0.43–3.04) 0.8 0.82 (0.27–2.53) 0.73
Body mass index:
T1 1 1
T2 2.83 (1.19–6.74) 0.02 3.34 (1.30–8.58) 0.01 1.95 (0.68–5.62) 0.22
T3 1.99 (0.81–4.91) 0.13 1.99 (0.75–5.26) 0.17 1.33 (0.44–3.99) 0.62
Waist circumference:
T1 1 1
T2 3.84 (1.57–9.37) <0.01 3.43 (1.34–8.77) 0.01 1.86 (0.67–5.13) 0.23
T3 1.97 (0.76–5.15) 0.17 1.77 (0.64–4.90) 0.27 0.82 (0.27–2.53) 0.73
The visceral adipose tissue area was divided into tertiles (T) as described in the Methods. The subcutaneous adipose tissue area was divided into tertiles as follows. In
patients with DM, T1 ≤ 110 cm2 (n = 40), 110 < T2 ≤ 155 cm2 (n = 41), T3 > 155 cm2 (n = 41). In patients without DM, T1 ≤ 92 cm2 (n = 111), 92 < T2 ≤ 150 cm2 (n = 112),
T3 > 150 cm2 (n = 111). The body mass index was divided into tertiles as follows. In patients with DM, T1 ≤ 22.72 kg/m2 (n = 40), 22.72 < T2 ≤ 25.2 kg/m2 (n = 41),
T3 > 25.2 kg/m2 (n = 41). In patients without DM, T1 ≤ 21.15 kg/m2 (n = 111), 21.15 < T2 ≤ 24.06 kg/m2 (n = 111), T3 > 24.06 kg/m2 (n = 112). The waist circumference
was divided into tertiles as follows. In patients with DM, T1 ≤ 81.5 cm (n = 40), 81.5 cm < T2 ≤ 91 cm (n = 41), T3 > 91 cm (n = 41). In patients without DM, T1 ≤ 77 cm
(n = 111), 77 < T2 ≤ 86 cm (n = 112), T3 > 86 cm (n = 111). Multivariate analyses were adjusted for age, male sex, hypertension, dyslipidemia, and current smoking.
DM, diabetes mellitus; CI, confidence interval.
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than in men [29]. In addition, smoking and inflamma-
tion (detected by a high CRP level) have been reported
to have a more negative influence on coronary artery
disease in women than in men. These sex differences
may affect the prevalence of vulnerable plaque in differ-
ent tertiles in patients without DM. However, our find-
ing that there was a similar proportion of men in the
highest tertile of the VAT area in patients with and with-
out DM suggests that sex differences did not have a
great impact on the associations between VAT and
plaque characteristics.
The results of this study show associations between
vulnerable coronary artery plaques and adiposity mea-
surements on CT. VAT area T3, BMI T2, and WC T2
were significantly associated with vulnerable plaque in
patients without DM. A previous study reported that a
large VAT area was significantly associated with both the
presence and extent of NCPs, whereas BMI and WC
were not [13]. One possible reason for this difference is
that they did not analyze these factors separately in pa-
tients with and without DM.
It is easier to evaluate adipose tissue attenuation and
volume on CT than on ultrasonography [30]. Recently,
the quality of abdominal fat attenuation has been re-
ported to be associated with cardiometabolic risk, sug-
gesting that evaluation of adipose tissue quality as well
as quantity may be useful [31]. Other studies reported
that epicardial adipose tissue was independently associ-
ated with coronary artery disease and coronary plaque
characteristics [32-35]. Further studies are needed to
clarify the associations between deposition of various
adipose tissues and coronary plaque characteristics.
Several limitations of this study should be considered.
First, this study was a single-center, retrospective study
that included only 456 Japanese patients with suspected
CAD. These subjects had a higher prevalence of risk fac-
tors than the general population, and the results may
not be applicable to the general population or to other
ethnicities. Further investigation in a larger population is
needed to definitively determine the associations among
VAT, vulnerable plaque, and DM. Second, adipocytokine
levels were not measured, and this study was unable to
determine a causal relationship between the amount
of VAT and plaque vulnerability. However, these bio-
markers are under investigation, and the lack of adipocy-
tokine data does not affect the relationship between
VAT and vulnerable plaque shown by this study. Third,
we excluded all patients with a history of coronary artery
stenting or coronary artery bypass graft surgery because
of the unreliability of coronary plaque assessment by
CTA in such patients. Although this resulted in exclu-
sion of 9% of the patients from our original study popu-
lation, this probably had minimal effects on the analyses.As the accuracy of detection of obstructive CAD is de-
creased in patients with a high coronary artery calcium
score [36,37], there is concern that the prevalence of
vulnerable plaque is underestimated in the higher VAT
tertiles of patients with DM. However, our finding that
there were no significant differences in coronary artery
calcium scores among the different tertiles in patients
with DM may alleviate concerns over this issue. Finally,
the latest consensus document on coronary CTA [38]
states that plaque characteristics in coronary CTA are
not well established. Even though this study assessed
plaque characteristics as previously reported [18], sub-
stantial additional technical developments will be re-
quired to define the usefulness of these characteristics in
terms of patient management.
In conclusion, the results of this study show that a
large VAT area is associated with characteristics of vul-
nerable coronary plaques on CTA in patients without
DM, but not in patients with DM. Our findings support
the hypothesis that VAT is a significant cardiometabolic
risk factor that is associated with vulnerable plaque be-
fore the development of DM. CTA findings may help to
improve risk stratification in such patients.
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